Create the future of medicine
„We are very pleased that the m4 Award and the BioM incubation program have already led to three successful company foundations..“
Dr. Petra Burgstaller, Senior Manager Start-Ups & Funding, BioM
The Bavarian “m4 Award” competition addresses academic research projects with spin-off potentials in the pre-seed phase. Its emphasis is on medical biotechnology. The program was launched in 2011 and has an annual budget of 2.5 million €. Academic research groups from Bavaria can apply for project funding of up to 500,000 € for two years. The purpose is to enhance and validate research results and to achieve a start-up phase. Successful projects receive not only financial but also consulting support from BioM, the relevant technology transfer organizations and other experts.
Scientist teams from universities, university hospitals and other publicly promoted research facilities in Bavaria can apply. The applied project should be defined by topic, time and budget and may not have started yet. Of course, all information exchanged within the scope of the m4 Award is confidentially treated. All application and publication rights remain with the applicants.
For further information on the two-stage procedure, please refer to the current call. Call 2017
Since 2016, the call annually alternates between medical biotechnology (m4 Award, guided by BioM) and health economics or medical technology (Medical Valley Award, guided by Medical Valley EMN).
In the years 2011, 2013 and 2015, a total of 15 innovative projects with spin-off potential have been awarded. Award Winners (in German)
The first spin-off was performed at the end of 2013, becoming Trianta Immunotherapies GmbH. This spin-off of the Helmholtz-Zentrum München, addressing personalized immunotherapies, was taken over by Martinsried-based Medigene AG in early 2014 and is known as Medigene Immunotherapies GmbH since late 2014.
In the same year, MetaHeps GmbH was founded, a spin-off of the LMU Munich. The company has developed an innovative platform technology for the prediction of drug-induced liver injury in individual patients.
Preomics GmbH is a spin-off of the Max Planck Institute of Biochemistry in Martinsried. The company was founded in early 2016 and develops innovative platform technologies forproteomic analyses for clinical applications.
Further spin-offs are currently under preparation.